Skye Bioscience released 52‑week interim data from the extension phase of its Phase 2a CBeyond study showing the nimacimab (peripherally‑restricted CB1 inhibitor) plus semaglutide combination produced 22.3% total weight loss at one year in the extension cohort. The company positioned the data as evidence that the combination can deliver clinically meaningful, sustained weight reduction. The results come after Skye’s initial Phase 2 setback on the primary endpoint and are being used to rebuild investor and clinical confidence. Skye emphasized the combination approach—pairing CB1 antagonism with GLP‑1 receptor agonism—as a potential route to enhance weight‑loss efficacy while managing safety; follow‑on studies and regulatory strategy will determine next steps.